For example, increased PD-L1 expression on tumor cells correlates with clinical benefit to anti-PD-1/PD-L1 ICI in patients with NSCLC, a trend that is observed in some but not all ICI-responsive malignancies [11]. Here, CD274 is linked to neoplasm.